<DOC>
	<DOCNO>NCT01160250</DOCNO>
	<brief_summary>This open-label , non-comparative , multicenter , expand access study Vismodegib ( GDC-0449 ) patient locally advance basal cell carcinoma ( BCC ) metastatic BCC ( mBCC ) otherwise without satisfactory treatment option .</brief_summary>
	<brief_title>A Study Vismodegib ( GDC-0449 ) Patients With Locally Advanced Metastatic Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>For patient mBCC , histologic confirmation distant BCC metastasis For patient locally advanced BCC , least one histologically confirm lesion 10 mm diameter write confirmation surgical specialist tumor consider inoperable surgery contraindicate For patient locally advanced BCC , radiotherapy must previously administer locally advanced BCC , unless radiotherapy contraindicate inappropriate . For patient whose locally advanced BCC irradiate , disease must progress radiation . Patients Gorlin syndrome may enroll study must meet criterion locally advance metastatic disease list Patients measurable and/or nonmeasurable disease ( defined RECIST ) allow Adequate organ function For woman childbearing potential , agreement use two acceptable method contraception , include one barrier method , study 12 month discontinuation Vismodegib ( GDC0449 ) For men female partner childbearing potential , agreement use latex condom , advise female partner use additional method contraception study 3 month discontinuation Vismodegib ( GDC0449 ) Pregnancy lactation Life expectancy &lt; 12 week Concurrent nonprotocolspecified antitumor therapy Completion recent antitumor therapy least 21 day prior initiation treatment Uncontrolled medical illness infection require treatment intravenous antibiotic History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Unwillingness practice effective birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>